Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX)
BCRX Stock Predictions and Ratings
WSX Rating:
HOLD
WSX Forecast (1yr):
4.30%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
161.30%
BCRX Stock Analysis
BCRX
PE Ratio:
BCRX
PEG Ratio:
Not Available
BCRX
Forward EPS Growth (12 month):
0.00%
BCRX
PS Ratio:
2
BCRX
PSG Ratio:
0.2
BCRX
Forward Revenue Growth (12 month):
8.80%
BCRX Articles
No data was found